2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, APL, Translational Research, MDS, Clinical Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult, Animal Model
PAPER

5207 Clinical and prognostic implications of minor clones in mixed phenotype acute leukemia: A retrospective cohort study

Chengcai Guo, Dong Lin2, Shouyun Li3, Kaiqi Liu4, Benfa Gong, MMSc5, Chunlin Zhou6, Ao Zhang7, Ying Wang, MD8, Yuntao Liu9, Qiuyun Fang10, Guangji Zhang11, Xiaoyuan Gong, MD12, Yan Li13, Yan Hui14, Ying Wang, MD, PhD15, Bingcheng LIU, MD16, Yingchang Mi, MD17, Hui Wei, MD, PhD18, Jianxiang Wang Sr, MD, PhD19, Shaowei Qiu, MD20
1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
2 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
4 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
5 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
6 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
7 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
8 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
9 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
10 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
11 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
12 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
13 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
14 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
15 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
16 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
17 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
18 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
19 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China
20 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Tianjin Institutes of Health Science, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS&PUMC), Tianjin 300020, China., Tianjin, China

Background

Mixed phenotype acute leukemia (MPAL) is a rare, heterogeneous entity with poor prognosis and no standardized treatment paradigm. The clinical significance of "minor clones"—defined as aberrant blast subpopulations comprising <5% of total blasts within a predominantly different-lineage leukemia—remains poorly defined. Whether minor-clone MPAL represents a distinct biological and prognostic subgroup requiring tailored therapeutic strategies is unknown.

Aims

This retrospective cohort study aimed to compare baseline characteristics, treatment patterns, response outcomes, and survival between MPAL patients with and without minor clones, and to characterize salvage strategies for induction failures.

Methods

We retrospectively analyzed 83 newly diagnosed MPAL patients (WHO 2022 criteria,BCR-ABL rearrangement were excluded) treated at our institution between 2018 and 2025. Patients were classified by multiparameter flow cytometry(MFC) into the minor-clone group (n=22; any aberrant blast subpopulation <5% of total blasts) and the non-minor-clone group (n=61; classic biphenotypic/bilineal MPAL). Induction regimens were categorized as AML-like, ALL-like, or mixed according to dominant lineage. Primary endpoints were complete remission (CR) rate, overall survival (OS), and event-free survival (EFS). Multivariable Cox regression was used to adjust for age, ELN 2022 risk category, complex karyotype, induction regimen, and HSCT status.

Results

The minor-clone group had a median age of 38 years (range, 13–71) and a median white blood cell (WBC) count of 6.6 × 10?/L (range, 0.66–128.7). Within this group, the majority of minor clones were of lymphoid lineage within a predominantly myeloid background, accounting for 20 out of 22 cases (90.9%). This included 19 cases of minor B-lymphoid clones and 1 case of a minor T-lymphoid clone. The remaining 2 cases (9.1%) exhibited minor myeloid clones in a predominantly lymphoid background. The minor-clone group had a higher normal karyotype rate (59.1% vs. 39.3%, P=0.04), lower complex karyotype rate (9.1% vs. 26.2%), and enrichment of myeloid-associated mutations (NRAS 45%, WT1 32%, RUNX1 27%, FLT3 27%), whereas the non-minor-clone group showed higher WBC counts and enrichment of lymphoid-associated mutations (NOTCH1 28%, DNMT3A 16%, JAK3 13%). Induction strategies diverged significantly: 68.2% of minor-clone patients received AML-like induction versus 18.0% in the non-minor-clone group (P<0.001), where 77.0% received ALL-like induction. CR rates after one cycle were comparable (63.6% vs. 70.0%, P=0.56), and cumulative two-cycle CR rates converged at 86.4% and 85.2%, respectively (P=0.91). Among non-responders after cycle 1 who achieved CR in cycle 2, all minor-clone patients received AML-type salvage (100%), while salvage in the non-minor-clone group was more heterogeneous (40% continued ALL-directed, 30% switched to AML-directed, 20% intensified AML-directed). With a median follow-up of 36 months (range, 6-72), median OS was not reached in either group. Three-year OS was 89.5% (95% CI: 76.7-100%) for the minor-clone group versus 73.5% (95% CI: 61.6-87.7%) for the non-minor-clone group (log-rank P=0.16). Three-year EFS was 64.2% versus 54.8%, respectively (P=0.70). HSCT rates were comparable (50.0% vs. 54.1%, P=0.72). On multivariable analysis adjusting for age, ELN risk, karyotype complexity, induction type, and HSCT, minor-clone status was not an independent predictor of OS (HR=0.52, 95% CI: 0.18-1.49, P=0.22) or EFS (HR=0.78, 95% CI: 0.38-1.61, P=0.51).

Conclusions

In this cohort, treatment directed at the dominant lineage yielded comparable CR rates between minor-clone and non-minor-clone MPAL. After adjusting for established prognostic factors, minor-clone status was not an independent predictor of survival, suggesting that the presence of minor clones (<5% of blasts) may not necessitate altering the induction strategy. Both induction and salvage therapies should focus on the dominant lineage. The non-minor-clone group exhibited greater genetic complexity and more divergent treatment approaches. Prognosis appears primarily driven by cytogenetic and molecular features rather than minor-clone status, though larger multicenter studies are needed to confirm these findings and to evaluate the potential role of minor clones as MRD markers.

Chengcai Guo: No relevant conflicts of interest to declare.